- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Identification of CD105 (endoglin) as novel risk marker in CLL ; volume:101 ; number:4 ; day:19 ; month:1 ; year:2022 ; pages:773-780 ; date:4.2022
Annals of hematology ; 101, Heft 4 (19.1.2022), 773-780, 4.2022
- Urheber
-
Greiner, Sarah M.
Märklin, Melanie
Holzmayer, Samuel
Kaban, Kübra
Meyer, Sophie
Hinterleitner, Clemens
Tandler, Claudia
Hagelstein, Ilona
Jung, Gundram
Salih, Helmut R.
Heitmann, Jonas S.
Kauer, Joseph
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-022-04756-4
- URN
-
urn:nbn:de:101:1-2022060423254435661199
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:31 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Greiner, Sarah M.
- Märklin, Melanie
- Holzmayer, Samuel
- Kaban, Kübra
- Meyer, Sophie
- Hinterleitner, Clemens
- Tandler, Claudia
- Hagelstein, Ilona
- Jung, Gundram
- Salih, Helmut R.
- Heitmann, Jonas S.
- Kauer, Joseph
- SpringerLink (Online service)
Ähnliche Objekte (12)
Identifizierung prädiktiver Marker bei CLL-Patienten mittels Datenmusterklassifizierung
Novel insights into the pathogenesis of chronic lymphocytic leukemia (CLL) and the identification of novel treatment strategies
Novel marker systems for forensic body fluid identification
Telomerverkürzung als neuer diagnostischer Marker bei der chronisch lymphatischen Leukämie (B-CLL)
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Identification of neutrophil activation markers as novel surrogate markers of CF lung disease
Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease
Imum, Continuatio CLL. Gryphiorum.
Identification of CD318 (CDCP1) as novel prognostic marker in AML
Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL
Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL
Identifizierung prädiktiver Marker bei CLL-Patienten mittels Datenmusterklassifizierung
Novel insights into the pathogenesis of chronic lymphocytic leukemia (CLL) and the identification of novel treatment strategies
Novel marker systems for forensic body fluid identification
Telomerverkürzung als neuer diagnostischer Marker bei der chronisch lymphatischen Leukämie (B-CLL)
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Identification of neutrophil activation markers as novel surrogate markers of CF lung disease
Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease
Imum, Continuatio CLL. Gryphiorum.
Identification of CD318 (CDCP1) as novel prognostic marker in AML
Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL
Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL
Identifizierung prädiktiver Marker bei CLL-Patienten mittels Datenmusterklassifizierung
Novel insights into the pathogenesis of chronic lymphocytic leukemia (CLL) and the identification of novel treatment strategies
Novel marker systems for forensic body fluid identification
Telomerverkürzung als neuer diagnostischer Marker bei der chronisch lymphatischen Leukämie (B-CLL)
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Identification of neutrophil activation markers as novel surrogate markers of CF lung disease
Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease
Imum, Continuatio CLL. Gryphiorum.
Identification of CD318 (CDCP1) as novel prognostic marker in AML
Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL
Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?